IRIS
BONATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.709
AS - Asia 2.434
EU - Europa 1.876
SA - Sud America 272
AF - Africa 119
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.418
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.625
SG - Singapore 951
CN - Cina 922
IE - Irlanda 315
IT - Italia 314
SE - Svezia 277
FI - Finlandia 258
DE - Germania 242
BR - Brasile 219
UA - Ucraina 214
HK - Hong Kong 188
VN - Vietnam 121
TR - Turchia 108
NL - Olanda 94
ZA - Sudafrica 77
CA - Canada 68
GB - Regno Unito 47
JP - Giappone 37
IN - India 29
RU - Federazione Russa 29
CI - Costa d'Avorio 27
AR - Argentina 23
AT - Austria 17
BE - Belgio 15
BD - Bangladesh 13
KR - Corea 13
MX - Messico 11
ES - Italia 10
EC - Ecuador 9
PL - Polonia 9
IQ - Iraq 8
CZ - Repubblica Ceca 7
AU - Australia 6
CL - Cile 6
ID - Indonesia 6
SA - Arabia Saudita 6
FR - Francia 5
MA - Marocco 5
EE - Estonia 4
IR - Iran 4
JO - Giordania 4
LT - Lituania 4
PK - Pakistan 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
KG - Kirghizistan 3
PY - Paraguay 3
RO - Romania 3
TN - Tunisia 3
TW - Taiwan 3
UY - Uruguay 3
VE - Venezuela 3
AM - Armenia 2
BG - Bulgaria 2
CH - Svizzera 2
CO - Colombia 2
KE - Kenya 2
LY - Libia 2
NG - Nigeria 2
TT - Trinidad e Tobago 2
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ML - Mali 1
MY - Malesia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.418
Salva come PNG Salva come JPEG
Città #
Singapore 464
Chandler 333
Jacksonville 322
Dublin 314
Beijing 262
Santa Clara 259
Ashburn 225
Hong Kong 186
Dallas 137
Nanjing 115
Ann Arbor 105
Boardman 100
Parma 99
Izmir 91
Dearborn 87
Johannesburg 75
Princeton 71
San Mateo 71
Jinan 49
Toronto 49
Wilmington 47
Munich 45
Los Angeles 42
Hebei 41
Ho Chi Minh City 40
Shenyang 40
Hefei 37
New York 36
Tokyo 35
Shanghai 33
Helsinki 31
Bologna 30
Des Moines 30
Nanchang 30
Abidjan 27
Kunming 27
Moscow 26
São Paulo 26
Hanoi 25
Columbus 21
Changsha 18
Düsseldorf 18
Guangzhou 17
Woodbridge 17
Tianjin 16
Turku 16
Brussels 15
Milan 15
Zhengzhou 14
London 13
Nuremberg 13
Falls Church 12
Fremont 11
Grafing 11
Haikou 11
Montreal 11
Kocaeli 10
Lanzhou 10
Rio de Janeiro 10
Seattle 10
Taizhou 10
Vienna 10
Amsterdam 9
Brooklyn 9
Buffalo 9
Jiaxing 9
Leawood 9
Chennai 8
Fuzhou 8
Modena 8
Seoul 8
The Dalles 8
Warsaw 8
Bremen 7
Chengdu 7
Falkenstein 7
Hangzhou 7
Houston 7
Hải Dương 7
Poplar 7
Redmond 7
Trezzano Sul Naviglio 7
Atlanta 6
Borås 6
Taiyuan 6
Ankara 5
Mumbai 5
Ningbo 5
Porto Alegre 5
Redwood City 5
San Francisco 5
Verona 5
Amman 4
Belo Horizonte 4
Boston 4
Chicago 4
Chongqing 4
Denver 4
Guayaquil 4
Haiphong 4
Totale 4.612
Salva come PNG Salva come JPEG
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 278
MEK1/2 KINASES DISABLE THE TUMOR SUPPRESSOR FUNCTIONS OF NATIVE BCR AND ABL1 KINASES TO IMPAIR ANTICANCER DRUGS’ RESPONSIVENESS IN TKI-RESISTANT PHILADELPHIA POSITIVE LEUKEMIAS 213
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 208
Elevated telomerase activity, minimal telomere loss in cord blood long-term cultures with extensive stem cell replication 135
Acenaphthenequinone thiosemicarbazone and its transition metal complexes: synthesis, structure, and biological activity. 128
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL 127
Early proinflammatory activation of renal tubular cells by normal and pathologic IgG 120
Biochemical, Immunological, and Molecular Markers of Hemopoietic Precursor Cells. 119
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 118
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 117
Treatment with Arsenic Trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells 115
Emerging MEK inhibitors 114
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 113
Arsenic Trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 112
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 111
Emerging Raf inhibitors 110
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 108
T cell receptor genes: a glance at normal and malignant hematopoiesis. 107
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. 105
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 105
p73 and p53 pathway in human breast cancers. 105
Arsenic Trioxide in hematological malignancies: the new discovery of an ancient drug. 104
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 104
T-cell receptor beta-chain gene rearrangement and expression during human thymic ontogenesis. 104
Discordant expression of terminal transferase and T cell receptor beta chain in fetal and pediatric thymocytes. 104
MDM2 inhibition synergistically enhances cytotoxicity of MEK1 inhibitor and Arsenic Trioxide (ATO) in AML blasts that retain a functional p53 pathway 102
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. 101
Su di un caso di sclerodermia associato ad aplasia midollare globale. 100
Ph1-positive acute myelocytic leukemia with high TdT levels. 100
Terminal deoxynucleotidyl transferase (TdT) levels in hairy cell leukemia. 99
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 99
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia 99
Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization. 98
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts 98
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. 97
Human T-cell receptor alpha chain gene during ontogeny 97
Synthesis, characterisation, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes 97
MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors 95
A micro-mechanically motivated model for the strength of heat-treated glass 93
Espressione degli antigeni CD1a, CD1b, CD1c in timo umano a diverse eta' dello sviluppo. 92
Synthesis, spectroscopic characterization and biological properties of new natural aldehydes thiosemicarbazones 91
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. 90
Hemopoiesis during human fetal life. Present knowledge and future prospects. 88
La linfoadenopatia angio-immunoblastica: Osservazioni cliniche, patologiche ed immunologiche su di un caso. 88
Expression of TCR beta chain gene N-diversity is not an early event in human thymic ontogeny 87
Terminal deoxynucleotidyl transferase: a nuclear marker of hemopoietic precursors. Biochemical, immunological and clinical aspects. 87
Synthesis, structure, spectroscopic properties and biological activity of mixed diorganotin(IV) complexes containing pyridine-2-carbaldehyde thiosemicarbazonato and diphenyldithiophosphinato ligands. 86
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent antitumor activity in NOD-SCID mice bearing advanced tumors of human multiple myeloma. 85
La mielofibrosi idiopatica asplenomegalica. Osservazioni cliniche e considerazioni su cinque casi. 84
Calibration of the Statistical-Interference Factors for the Design of Tempered Structural Glass 83
The fine structure of HNK-1 (Leu7) positive cells. A study using an immunoperoxidase technique. 83
Phenotype of the terminal transferase-positive cells in human foetal liver and bone-marrow: analysis with monoclonal antibodies. 83
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. 82
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 82
Terminal deoxynucleotidyl transferase (TDT) expression correlates with the presence of N regions during human thymic ontogeny 81
Valutazione dell'attivita proliferativa delle cellule emopoietiche nelle sindromi preleucemiche. 80
The combination of MEK inhibitors and Arsenic Trioxide triggers in vitro and in vivo synergistic cytotoxicity in multiple myeloma through multiple signaling pathways 79
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. 79
Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. 78
TCR beta chain expression during human thymic development. 78
Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival. 77
Terminal deoxynucleotidyl transferase-positive B cell precursors in fetal lymph nodes and extrahemopoietic tissues. 75
Terminal deoxynucleotidyl transferase in human fetal tissues. 74
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 73
Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. 70
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 70
null 69
Selective Expression and Constitutive Phosphorylation of SHC Proteins in the CD34+ Fraction of Chronic Myelogenous Leukemias. 69
Terminal deoxynucleotidyl transferase (TdT) in human foetuses. An immunofluorescent and biochemical study. 69
Leu-7-positive cells with monocyte phenotype show different ultrastructural features in comparison to Leu-7-positive cells with T-cell phenotype. 67
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways 66
Medicina molecolare: nuovi strumenti per la conoscenza e la cura delle patologie dell'uomo. 65
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. 64
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. 63
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 59
Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb. 59
null 30
Totale 7.444
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021305 0 0 0 0 0 17 35 13 111 19 101 9
2021/2022382 5 10 0 14 12 16 63 72 20 34 18 118
2022/20231.178 139 124 94 87 106 123 5 69 379 14 30 8
2023/2024407 33 47 17 8 55 68 24 9 15 23 34 74
2024/20251.649 60 92 105 60 212 201 38 76 227 144 121 313
2025/20261.625 291 278 356 255 404 41 0 0 0 0 0 0
Totale 7.444